Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02833506
Recruitment Status : Withdrawn (production of adjuvant to be used with vaccine was discontinued by sponsor)
First Posted : July 14, 2016
Last Update Posted : May 1, 2018
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Roswell Park Cancer Institute

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : August 15, 2018
Estimated Study Completion Date : August 15, 2019